Gold Peter A, Ng Terence Y, Coury Josephine R, Garbarino Luke J, Sodhi Nipun, Mont Michael A, Scuderi Giles R
Department of Orthopaedic Surgery, Long Island Jewish Medical Center, Northwell Health, Queens, NY, USA.
Donald and Barbara Zucker School of Medicine at Hofstra, Northwell Health, Hempstead, NY, USA.
J Orthop. 2020 Jul 23;21:345-349. doi: 10.1016/j.jor.2020.07.005. eCollection 2020 Sep-Oct.
Venous thromboembolism (VTE) has a 30-day mortality rate of between 10 and 30%. The Caprini score is a VTE risk assessment model, which assigns points to 20 past medical history and current health factors. We hypothesized that the Caprini score could predict VTE incidence and recommend prophylaxis following total joint arthroplasty.
We performed a retrospective review of prospectively collected institutional data identifying Caprini scores on 2155 primary hip (n = 840) and knee (n = 1315) arthroplasties. Surgeons were blinded to Caprini scores when prescribing VTE prophylaxis. Patients were separated into prophylaxis groups receiving Aspirin (81 mg BID or 325 mg BID) or other (Rivaroxaban, Warfarin, Enoxaparin, Apixaban, Dabigatran, Heparin). Univariate, multivariate, and Cohen's effect size analyses assessed the predictive power of the Caprini score on VTE incidence.
The mean Caprini score was 9.49 (5-25). A majority, 83% (1792) of patients were in the Aspirin group, and 17% (363) in the other group. Other prophylaxis patients had statistically significantly higher Caprini scores (10 vs. 9, p < 0.0001). Twenty-five (1.2%) patients developed VTE. Controlling for prophylaxis, higher Caprini scores increased VTE risk, but this wasn't statistically significant (p = 0.16). Multivariate analysis showed a non-significant effect for patients with BMIs >40 or Caprini scores ≥11 to predict VTE incidence in the Aspirin or other prophylaxis groups (p = 0.52 and p = 0.15 respectively). Cohen's effect size was small, comparing Caprini scores in patients who had and had not had a VTE in both Aspirin and other prophylaxis groups (Cohen's d = 0.25 and d = 0.16 respectively).
Surgeons rely on stronger pharmacologic prophylaxis for a select high risk group of their primary lower extremity total joint arthroplasty patients. When controlling for prophylaxis, the Caprini score had a small effect size and did not have the predictive power necessary to guide treatment.
静脉血栓栓塞症(VTE)的30天死亡率在10%至30%之间。Caprini评分是一种VTE风险评估模型,它根据20项既往病史和当前健康因素来打分。我们假设Caprini评分可以预测全关节置换术后的VTE发生率并推荐预防措施。
我们对前瞻性收集的机构数据进行了回顾性分析,确定了2155例初次髋关节置换术(n = 840)和膝关节置换术(n = 1315)患者的Caprini评分。外科医生在开VTE预防药物时对Caprini评分不知情。患者被分为接受阿司匹林(81毫克每日两次或325毫克每日两次)或其他药物(利伐沙班、华法林、依诺肝素、阿哌沙班、达比加群、肝素)的预防组。单因素、多因素和科恩效应量分析评估了Caprini评分对VTE发生率的预测能力。
Caprini评分的平均值为9.49(5 - 25)。大多数患者,即83%(1792例)在阿司匹林组,17%(363例)在其他组。接受其他预防措施的患者Caprini评分在统计学上显著更高(10分对9分,p < 0.0001)。25例(1.2%)患者发生了VTE。在控制预防措施的情况下,较高的Caprini评分增加了VTE风险,但这在统计学上不显著(p = 0.16)。多因素分析显示,体重指数>40或Caprini评分≥11的患者在阿司匹林组或其他预防组中预测VTE发生率的作用不显著(分别为p = 0.52和p = 0.15)。在阿司匹林组和其他预防组中,比较发生和未发生VTE的患者的Caprini评分,科恩效应量较小(分别为科恩d = 0.25和d = 0.16)。
对于一部分下肢初次全关节置换术的高危患者,外科医生依赖更强效的药物预防措施。在控制预防措施的情况下,Caprini评分的效应量较小,且没有指导治疗所需的预测能力。